Skip to Content
  • Tracked for
    Impact Factor
  • 29 days
    Submission to First Decision
  • 4 days
    Acceptance to Publication

Sclerosis

Sclerosis is an international, peer-reviewed, open access journal on sclerosis and related diseases, published quarterly online by MDPI.
  • Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
  • High Visibility: indexed within ESCI (Web of Science), Embase, and other databases.
  • Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.4 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2026).
  • Recognition of Reviewers: Reviewers whose reports are timely and of high quality receive an APC discount voucher for a future publication in an MDPI journal. Become a reviewer.
  • Sclerosis is a companion journal of JCM.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (117)

  • Review
  • Open Access

Systemic sclerosis (SSc) combines fibrosis, vasculopathy, and immune dysregulation, but how abnormalities across cellular compartments integrate remains incompletely understood. Reduced FLI1 expression has been reported in several SSc-relevant compartments, through inherited, epigenetic, and signaling-dependent mechanisms demonstrated in specific settings. Experimental perturbation reveals lineage-dependent reprogramming: fibroblasts acquire profibrotic features, endothelial cells lose vascular homeostatic identity, epithelial perturbation produces activation and tolerance-related abnormalities, and B-lineage loss alters development and subset distribution, with dendritic-cell and myeloid findings providing supporting evidence. Lineage-targeted loss demonstrates phenotypic capacity, partial Fli1 reduction sensitizes to additional injury, and combined Klf5/Fli1 insufficiency supports cooperative susceptibility. These states may converge on fibrotic, vascular, and immune disease modules, although the complete network has not been reconstructed and human organ tropism remains unexplained. FLI1 is therefore best viewed as a multicellular susceptibility and phenotype-shaping factor whose effects depend on lineage, dosage, context, and cooperating abnormalities.

Sclerosis

11 November 2026

Cell-specific FLI1-dependent reprogramming in SSc. Reduced FLI1 in fibroblasts is linked to matrix activation; endothelial Fli1 loss disrupts vascular homeostasis, with Tie2-lineage specificity requiring appropriate qualification; epithelial loss produces activation and experimental tolerance-related pathology; B-lineage deletion alters B-cell development and ABC-like states, whereas human B-cell observations do not establish molecular equivalence. Dendritic-cell evidence links reduced FLI1 in human CD11c+ cells with altered RALDH-associated function in a global Fli1-haploinsufficient/BLM model, and myeloid evidence combines human monocyte and experimental perturbation data. Visual prominence reflects evidentiary role in this review, not biological importance. H = observation from human SSc samples; E = consequence of experimental FLI1/Fli1 perturbation.
  • Review
  • Open Access

Systemic sclerosis (SSc) is a clinically distinct autoimmune connective tissue disease characterized by immune dysregulation, vasculopathy, and excessive fibrosis. Monocytes and macrophages (Mo/Mφ) contribute to these processes through heterogeneous tissue-dependent states that are not sufficiently represented by a binary M1/M2 framework. Human blood and tissue studies, including recent single-cell and spatial analyses, have repeatedly identified hybrid activated monocytes and monocyte-derived macrophages associated with skin or lung involvement. Classical studies have established several Mo/Mφ-linked profibrotic mechanisms in SSc, including the secretion of cytokines, chemokines, and growth factors; organization of macrophage–stromal signaling niches; production and remodeling of the extracellular matrix; monocyte plasticity toward vascular and mesenchymal lineages; and defective efferocytosis and resolution. Upstream of these effector outputs, transcriptional, epigenetic, and metabolic programs are increasingly recognized as key regulators. As one example relevant to Mo/Mφ differentiation, we have focused on interferon regulatory factor 8 (IRF8), showing reduced IRF8 expression in circulating monocytes from diffuse cutaneous SSc associated with skin fibrosis. Experimentally, IRF8 silencing and myeloid-specific Irf8 deletion promote profibrotic features; however, the functional direction of IRF8 across lineages and tissues remains incompletely defined. Several established and emerging SSc therapeutic strategies are thought to act at least in part on the Mo/Mφ compartment, although direct SSc-derived cellular evidence remains limited. This review synthesizes Mo/Mφ diversity and effector functions in SSc and outlines therapeutic implications, highlighting the need for lineage- and tissue-resolved profiling of Mo/Mφ and mechanistic dissection of their upstream programs as a foundation for rational therapeutic strategies in SSc.

Sclerosis

11 November 2026

  • Review
  • Open Access

Safety and Outcomes of Immune Checkpoint Inhibitor Therapy in Systemic Sclerosis: A Scoping Review

  • Jennifer George,
  • Michalah O’Connell and
  • Hanna K. Jensen
  • + 1 author

With their success in the treatment of various malignancies, immune checkpoint inhibitors (ICIs) are quickly being established as a critical component of treatment plans in oncology. However, due to concerns regarding autoimmune flares and immune-related adverse events, patients with autoimmune disease have historically been excluded from clinical trials. While research has been slowly incorporating those with autoimmune disease, research focusing on some autoimmune diseases such as systemic sclerosis is still lacking. This scoping review aimed to characterize the safety and outcomes of immune checkpoint inhibitor therapy in patients with systemic sclerosis. A literature search conducted through PubMed, Semantic Scholar, and OpenAlex was performed through June 2026 in accordance with the PRISMA-Scoping Review guidelines. Available evidence regarding the safety of ICI therapy in patients with pre-existing systemic sclerosis remains limited and heterogeneous. Autoimmune flares and immune-related adverse events, including severe complications, have been reported, and the available data are insufficient to establish the safety or tolerability of ICIs in this population. Further prospective studies are needed to better characterize outcomes and identify factors associated with increased risk.

Sclerosis

10 October 2026

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Sclerosis - ISSN 2813-3064